Aragen announced the establishment of a new biologics manufacturing facility in Bangalore, India. The state-of-the-art facility is part of a $30 million investment covering nearly 160,000 square meters and includes process development laboratories and a number of Good Manufacturing Practice (GMP) supporting functions such as quality control laboratories (analytical and microbiology). The production facilities will be equipped for advanced processing using single-use bioreactors and advanced post-treatment facilities to serve its rapidly growing biological customer base.
The facility offers integrated solutions for process development, process validation, analytical development, pilot production, large-scale DS production and stability services. It has the ability to develop and manufacture mAbs, therapeutic proteins and fusion proteins to expand the company's biomanufacturing capabilities in California.
The process development laboratory is scheduled to be operational by the third quarter of FY 24, while the first manufacturing suite will open in the third quarter of FY 25. The facility is designed to include plasmid DNA, mRNA, cell and gene therapy, microbial manufacturing and additional GMP manufacturing suites in the future as demand ramps up.
We use cookies to ensure you get the best experience on our website. Read more...
